Serum free light chains: Diagnostic and prognostic value in multiple myeloma

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 9, 2009, Pages 1101-1107

  Sthaneshwar, Pavai ^a   Nadarajan, Veerasekaran ^a   Maniam, Jayaranee A S ^a   Nordin, Nani ^a   Gin Gin, Gan ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

2 microglobulin; Multiple myeloma; Serum electrophoresis; Serum free light chains

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; PROTEIN; TUMOR MARKER;

AGED; ARTICLE; ASSAY; CALCULATION; CANCER DIAGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GAMMOPATHY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; INFORMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; POLYCLONAL IMMUNOGLOBULINEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ELECTROPHORESIS;

AGED; BLOOD PROTEIN ELECTROPHORESIS; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 70349490137     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.260     Document Type: Article

References (26)

1. Merlini G. Monoclonal gammopathies. Cancer J 1995;8: 173-180
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report or the International Myeloma Working Group. Br J Haematol 2003;121: 749-757
3. Bradwell AR, Car-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491
4. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444
5. Le Bricon T, Bengoufa D, Benlakehal M, Bousquet B, Erlich D. Urinary free light chain analysis by the Freelite immunoassay: a preliminary study in multiple myeloma. Clin Biochem 2002;35:565-567
6. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680
7. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukaemia 2008;22:1933-1937
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;58:457-481
9. Wolff F, Thiry C, Willems D. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy. Clin Biochem 2007;40:351-354
10. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with non-secretory multiple myeloma. Blood 2001;97:2900-2902
11. Bratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008;141:413-422
12. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354
13. Tate JR, Gill D, Cobcroft R, Hickman PE. Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257 (Pubitemid 36900609)
14. Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009;131:166-171
15. Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005;84: 588-593
16. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008;54:1823-1830
17. Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med 1967;42:937-948
18. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854
19. Yun JP, Suh C, Lee E, Chang JW, Yang WS, Park JS, et al. Comparison of serum B-2 microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma. J Korean Med Sci 2006;21:639-644
20. Facon T, Abet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Chromsome 13 abnormalities identified by FISH analysis and serum beta 2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97: 1566-1571
21. Cuzick J, De Stavola BL, Cooper EH. Long-term prognostic value of serum B-2-microglobulin in myelomatosis. Br J Haematol 1990;75:506-510
22. Bataille R, Greiner J, Sany J. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis and treat-ment: a prospective study of 160 patients. Blood 1984; 63:468-476
23. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). Br J Haematol 1997;96:103-110
24. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-832
25. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007;137:240-243
26. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-224